ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $255,000 | -24.8% | 5,000 | 0.0% | 0.01% | -38.5% |
| Q1 2017 | $339,000 | -75.9% | 5,000 | -75.0% | 0.01% | -80.9% |
| Q4 2016 | $1,406,000 | -7.8% | 20,000 | -7.0% | 0.07% | -27.7% |
| Q3 2016 | $1,525,000 | +42.5% | 21,500 | -1.7% | 0.09% | +13.3% |
| Q2 2016 | $1,070,000 | -32.4% | 21,870 | -12.5% | 0.08% | +20.3% |
| Q1 2016 | $1,583,000 | -5.9% | 25,000 | +66.7% | 0.07% | -40.5% |
| Q4 2015 | $1,683,000 | +16.5% | 15,000 | 0.0% | 0.12% | +81.2% |
| Q3 2015 | $1,445,000 | -90.2% | 15,000 | -89.5% | 0.06% | -89.0% |
| Q2 2015 | $14,686,000 | +64.9% | 143,432 | 0.0% | 0.58% | +46.8% |
| Q1 2015 | $8,906,000 | +43.5% | 143,432 | +1.4% | 0.40% | +84.6% |
| Q4 2014 | $6,206,000 | -22.5% | 141,432 | 0.0% | 0.21% | +9.2% |
| Q3 2014 | $8,005,000 | +125.2% | 141,432 | +78.6% | 0.20% | +154.5% |
| Q2 2014 | $3,555,000 | -3.5% | 79,200 | +5.1% | 0.08% | +4.1% |
| Q1 2014 | $3,684,000 | – | 75,350 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |